Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 1
2001 4
2002 8
2003 3
2004 2
2005 3
2006 4
2007 6
2008 5
2009 4
2010 2
2011 10
2012 2
2013 7
2014 2
2015 1
2016 3
2017 11
2018 9
2019 4
2020 6
2021 5
2022 9
2023 5
2024 8
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Lipoprotein glomerulopathy.
Tsimihodimos V, Elisaf M. Tsimihodimos V, et al. Curr Opin Lipidol. 2011 Aug;22(4):262-9. doi: 10.1097/MOL.0b013e328345ebb0. Curr Opin Lipidol. 2011. PMID: 21464714 Review.
Pathophysiology of Diabetic Dyslipidaemia.
Filippatos T, Tsimihodimos V, Pappa E, Elisaf M. Filippatos T, et al. Among authors: tsimihodimos v. Curr Vasc Pharmacol. 2017;15(6):566-575. doi: 10.2174/1570161115666170201105425. Curr Vasc Pharmacol. 2017. PMID: 28155609 Review.
Lipidomics in non-alcoholic fatty liver disease.
Kartsoli S, Kostara CE, Tsimihodimos V, Bairaktari ET, Christodoulou DK. Kartsoli S, et al. Among authors: tsimihodimos v. World J Hepatol. 2020 Aug 27;12(8):436-450. doi: 10.4254/wjh.v12.i8.436. World J Hepatol. 2020. PMID: 32952872 Free PMC article. Review.
SGLT1 inhibition: Pros and cons.
Tsimihodimos V, Filippas-Ntekouan S, Elisaf M. Tsimihodimos V, et al. Eur J Pharmacol. 2018 Nov 5;838:153-156. doi: 10.1016/j.ejphar.2018.09.019. Epub 2018 Sep 18. Eur J Pharmacol. 2018. PMID: 30240793 Review.
Incretins and Lipid Metabolism.
Tsimihodimos V, Elisaf M. Tsimihodimos V, et al. Curr Med Chem. 2018;25(18):2133-2139. doi: 10.2174/0929867324666170414164244. Curr Med Chem. 2018. PMID: 28413961 Review.
PCSK9 and carbohydrate metabolism: A double-edged sword.
Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. Filippatos TD, et al. Among authors: tsimihodimos v. World J Diabetes. 2017 Jul 15;8(7):311-316. doi: 10.4239/wjd.v8.i7.311. World J Diabetes. 2017. PMID: 28751953 Free PMC article.
Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus.
Filippas-Ntekouan S, Dimou A, Dafopoulos P, Kostara C, Bairaktari E, Chasapi S, Spyroulias G, Koufakis T, Koutsovasilis A, Tsimihodimos V. Filippas-Ntekouan S, et al. Among authors: tsimihodimos v. J Diabetes Metab Disord. 2024 Dec 16;24(1):4. doi: 10.1007/s40200-024-01508-1. eCollection 2025 Jun. J Diabetes Metab Disord. 2024. PMID: 39697865
122 results